“Being part of the TMC Innovation Accelerator program is a great opportunity for us as it provides access to a unique environment at the forefront of science and innovation – the best place to take patient care to the next level,“ says Marija Plodinec, CEO of ARTIDIS. “It also enables us to further strengthen ongoing scientific and clinical collaborations focusing on breast, lung and pancreatic cancer with our colleagues from three major institutions within the Texas Medical Center.”
ARTIDIS is one of the 16 startups selected worldwide from more than 140 competing healthcare companies for the 9th TMC accelerator medical device cohort. After completing the TMC Accelerator Program that culminated with a Demo Day presentation on November 7th, 2019, ARTIDIS is now embedded in the world's largest medical center. As part of this unique ecosystem, the startup is in the process of introducing its high-end technology into the US market to generate added value for patients and the healthcare system.
ARTIDIS AG is a spin off from the lab of Argovia Prof. Roderick Lim at the Biozentrum and the Swiss Nanoscience Institute, University of Basel. The startup has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. ARTIDIS’ nanotechnology platform integrates different types of clinical data, allowing physicians to significantly shorten the current diagnostic process to benefit both the patient and the healthcare system. ARTIDIS enables professionals to design personalized cancer treatment plans tailored to the individual patient needs and desired outcomes.
The TMC Innovation Accelerator program
Texas Medical Center (TMC) — the largest “medical city” in the world — is at the forefront of advancing life sciences. TMC is pioneering patient care, research and technology, education and prevention. The TMC Innovation Accelerator (TMCx) is a program that aims at impacting the healthcare industry by fostering integration of cutting-edge technology in the clinics.